Asia PacificENPublic regulatory overview
Vietnam
Country Overview Population: Approximately 99 million (2024); median age approximately 31 years; rapidly urbanizing Healthcare system: Universal health insurance (BHYT — Bảo hiểm y...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAModerate benefitFDA evidence is useful technical and clinical support, but the local authority still performs an independent review.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRStrong benefitCE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditIndirect QMS signalMDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingSupportive evidenceNMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: Vietnam
- Product line: Medical devices
- Regulator / source: Regulatory maturity: Low to moderate, with rapid recent development but notable instability at the implementation level. DAV (Drug Administration of Vietnam) review capacity is still developing. Post-COVID backlog (2020–2022) has not been fully cleared. The regulatory framework references ASEAN/IMDRF but is substantially localized with complex requirements.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Market characteristics: Market size approximately USD 2.0 billion in 2023, with approximately 10% annual growth. Import dependence is very high (approximately 75%). Germany, Japan, and the US are the primary import sources. Domestic manufacturers have made some inroads in basic equipment but remain limited overall. Vietnam's rapid economic growth is driving increasing demand for premium private healthcare.
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Country Overview
- Population: Approximately 99 million (2024); median age approximately 31 years; rapidly urbanizing
- Healthcare system: Universal health insurance (BHYT — Bảo hiểm y tế) covers approximately 93% of the population, but reimbursement levels are limited. Public hospitals dominate (approximately 85% of healthcare resources); private hospitals are growing rapidly. Healthcare infrastructure is concentrated in Hanoi (north) and Ho Chi Minh City (south).
- Market characteristics: Market size approximately USD 2.0 billion in 2023, with approximately 10% annual growth. Import dependence is very high (approximately 75%). Germany, Japan, and the US are the primary import sources. Domestic manufacturers have made some inroads in basic equipment but remain limited overall. Vietnam's rapid economic growth is driving increasing demand for premium private healthcare.
- Regulatory maturity: Low to moderate, with rapid recent development but notable instability at the implementation level. DAV (Drug Administration of Vietnam) review capacity is still developing. Post-COVID backlog (2020–2022) has not been fully cleared. The regulatory framework references ASEAN/IMDRF but is substantially localized with complex requirements.
Regulatory Authority
- Primary authority: DAV (Drug Administration of Vietnam — Cục Quản lý Dược), under the Ministry of Health (MOH — Bộ Y tế). Note: Following the 2023 institutional reform, medical device regulatory functions were consolidated under DAV (previously under the Medical Equipment and Construction Division — DTBYT). Verify the current institutional name when submitting.
- Official portal: https://dav.gov.vn; Medical device registration system: https://dichvucong.moh.gov.vn (MOH Public Services Portal)
- Key regulations:
- Decree No. 98/2021/ND-CP on Medical Device Management (effective November 2021; supersedes Decree 36/2016)
- Circular No. 05/2022/TT-BYT (implementing regulations for Decree 98/2021)
- Circular on Medical Device Classification Guidelines
- Historical reference: Decree 36/2016 (superseded), Circular 30/2015 (updated)
Device Classification System
| Local Class | Risk Level | Approximate EU/FDA Equivalent | Notes |
|---|---|---|---|
| Type A (Loại A) | Lowest risk | EU Class I / FDA Class I | Declaration/notification (khai báo); relatively simple procedure |
| Type B (Loại B) | Low-Moderate risk | EU Class IIa / FDA Class II | Full marketing authorization required (đăng ký lưu hành); faster review |
| Type C (Loại C) | Moderate-High risk | EU Class IIb / FDA Class III | Marketing authorization required; rigorous review with technical verification |
| Type D (Loại D) | Highest risk | EU Class III / FDA PMA | Most stringent review; complete technical documentation + local technical testing required |
Note: Classification is based on the annexes of Decree 98/2021. Classification requests can be submitted to DAV (approximately 4–8 weeks for a determination). IVD products follow a separate classification scheme (based on the WHO IVD classification framework).
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.